Cart
sales@molnova.com
Galcanezumab
CAS No. 1578199-75-3
Galcanezumab( —— )
Catalog No. M36662 CAS No. 1578199-75-3
Galcanezumab is a humanized IgG4 monoclonal antibody targeting the CGRP ligand, which binds to the ligand calcitonin gene-related peptide. Galcanezumab can be used to prevent and treat migraines or cluster headaches.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 376 | In Stock |
|
| 10MG | 603 | In Stock |
|
| 25MG | 934 | In Stock |
|
| 50MG | 1228 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGalcanezumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionGalcanezumab is a humanized IgG4 monoclonal antibody targeting the CGRP ligand, which binds to the ligand calcitonin gene-related peptide. Galcanezumab can be used to prevent and treat migraines or cluster headaches.
-
DescriptionGalcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetCGRP Receptor
-
RecptorCGRP Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1578199-75-3
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Yvette N Lamb. Galcanezumab: First Global Approval. Drugs. 2018 Nov;78(16):1769-1775.?
molnova catalog
related products
-
Olcegepant (hydrochl...
The first small molecule selective CGRP antagonist with Ki of 14.4 nM for hCGRP.
-
Olcegepant
The first small molecule selective CGRP antagonist with Ki of 14.4 nM for hCGRP.
-
α-CGRP (human)
Endogenous calcitonin gene-related peptide receptor (CGRP) agonist.
